eltrombopag indications/contra

Stem definitionDrug idCAS RN
4399 496775-61-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • eltrombopag
  • SB 497115
  • revolade
  • eltrombopag olamine
  • ppromacta
an oral, nonpeptide thrombopoietin receptor agonist
  • Molecular weight: 442.48
  • Formula: C25H22N4O4
  • CLOGP: 5.25
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 3
  • TPSA: 114.59
  • ALOGS: -4.63
  • ROTB: 5

Drug dosage:

DoseUnitRoute
50 mg O

Approvals:

DateAgencyCompanyOrphan
March 11, 2010 EMA
Nov. 20, 2008 FDA NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 912.63 36.22 275 2933 27193 3355458
Death 538.41 36.22 305 2903 152019 3230632
Drug ineffective 530.64 36.22 276 2932 115814 3266837
Platelet count increased 474.72 36.22 107 3101 3264 3379387
Pulmonary embolism 268.77 36.22 112 3096 27776 3354875
Myelofibrosis 249.55 36.22 49 3159 743 3381908
Thrombocytopenia 203.38 36.22 99 3109 35169 3347482
Immune thrombocytopenic purpura 175.49 36.22 45 3163 2364 3380287
Deep vein thrombosis 169.77 36.22 75 3133 21314 3361337
Headache 166.18 36.22 122 3086 91858 3290793
Acute myeloid leukaemia 158.20 36.22 49 3159 5124 3377527
Bone marrow reticulin fibrosis 151.63 36.22 25 3183 127 3382524
Liver disorder 147.12 36.22 55 3153 10168 3372483
Sepsis 145.87 36.22 77 3131 32296 3350355
Haemorrhage 142.55 36.22 65 3143 19856 3362795
Portal vein thrombosis 135.32 36.22 31 3177 1006 3381645
Myelodysplastic syndrome 133.57 36.22 44 3164 5603 3377048
Pyrexia 129.40 36.22 100 3108 81015 3301636
Cerebral infarction 124.32 36.22 46 3162 8254 3374397
Thrombocytosis 117.43 36.22 29 3179 1303 3381348
Febrile neutropenia 114.32 36.22 55 3153 18920 3363731
Pneumonia 112.91 36.22 87 3121 70056 3312595
Haematological malignancy 110.96 36.22 20 3188 184 3382467
Anaemia 106.71 36.22 76 3132 54257 3328394
Thrombosis 103.95 36.22 47 3161 14043 3368608
Epistaxis 99.67 36.22 46 3162 14405 3368246
Platelet count abnormal 92.76 36.22 23 3185 1050 3381601
Fatigue 91.93 36.22 93 3115 107147 3275504
Acute myocardial infarction 78.26 36.22 37 3171 12214 3370437
Chronic lymphocytic leukaemia 75.96 36.22 20 3188 1162 3381489

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC B02BX05 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Other systemic hemostatics
FDA PE N0000175969 Increased Megakaryocyte Maturation
FDA PE N0000175970 Increased Platelet Production
FDA EPC N0000175973 Thrombopoietin Receptor Agonist
FDA MoA N0000175968 Thrombopoietin Receptor Agonists
FDA MoA N0000190107 Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA MoA N0000191272 UGT1A1 Inhibitors
FDA MoA N0000191275 UGT1A3 Inhibitors
FDA MoA N0000191276 UGT1A4 Inhibitors
FDA MoA N0000191277 UGT1A6 Inhibitors
FDA MoA N0000191278 UGT1A9 Inhibitors
FDA MoA N0000191273 UGT2B7 Inhibitors
FDA MoA N0000191274 UGT2B15 Inhibitors
FDA EPC N0000178368 Thrombopoiesis Stimulating Agent
FDA MoA N0000175967 Thrombopoietin Receptor Interactions

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Chronic idiopathic thrombocytopenic purpura indication 13172003 DOID:8924
Thrombocytosis contraindication 6631009 DOID:2228
Hyperbilirubinemia contraindication 14783006 DOID:2741
Acute hepatitis contraindication 37871000
Hepatic vein thrombosis contraindication 38739001 DOID:11512
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:2527
Bilateral cataracts contraindication 95722004
Myelodysplastic syndrome contraindication 109995007
Liver function tests abnormal contraindication 166603001
Acute hepatic failure contraindication 197270009
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Thromboembolic disorder contraindication 371039008
Increased Reticulin Bone Marrow Deposition contraindication
Predisposition to Thrombosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.16 acidic
pKa2 3.76 acidic
pKa3 10.67 acidic
pKa4 1.34 Basic
pKa5 0.59 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 6280959 Oct. 30, 2018 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 6280959 Oct. 30, 2018 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 6280959 Oct. 30, 2018 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL 6280959 Oct. 30, 2018 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7332481 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7452874 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7473686 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7790704 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7332481 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7452874 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7473686 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7790704 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7452874 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7452874 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7332481 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7452874 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7473686 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7790704 May 24, 2021 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL 7332481 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL 7473686 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL 7790704 May 24, 2021 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7160870 Nov. 20, 2022 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7160870 Nov. 20, 2022 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7160870 Nov. 20, 2022 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL 7160870 Nov. 20, 2022 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7795293 May 21, 2023 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7795293 May 21, 2023 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7795293 May 21, 2023 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7795293 May 21, 2023 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL 7795293 May 24, 2023 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7547719 July 13, 2025 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7547719 July 13, 2025 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7547719 July 13, 2025 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL 7547719 July 13, 2025 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 8052995 Aug. 1, 2027 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL 8052995 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8052993 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8052994 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8062665 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8071129 Aug. 1, 2027 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8071129 Aug. 1, 2027 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8071129 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8071129 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052993 Aug. 1, 2027 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052993 Aug. 1, 2027 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052993 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052993 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052994 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8062665 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8071129 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052993 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052994 Aug. 1, 2027 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052994 Aug. 1, 2027 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052994 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8052994 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8062665 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8071129 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8052993 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8052994 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8062665 Aug. 1, 2027 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8062665 Aug. 1, 2027 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8062665 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8062665 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8071129 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL 8828430 Aug. 1, 2027 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL June 11, 2018 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL June 11, 2018 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL June 11, 2018 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL June 11, 2018 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL June 11, 2018 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL June 11, 2018 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL June 11, 2018 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL June 11, 2018 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL June 11, 2018 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL June 11, 2018 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL June 11, 2018 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL June 11, 2018 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL Dec. 11, 2018 PEDIATRIC EXCLUSIVITY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL Dec. 11, 2018 PEDIATRIC EXCLUSIVITY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL Dec. 11, 2018 PEDIATRIC EXCLUSIVITY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL Dec. 11, 2018 PEDIATRIC EXCLUSIVITY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL Dec. 11, 2018 PEDIATRIC EXCLUSIVITY
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL Dec. 11, 2018 PEDIATRIC EXCLUSIVITY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL Aug. 26, 2021 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL Aug. 26, 2021 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL Aug. 26, 2021 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL Aug. 26, 2021 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL Aug. 26, 2021 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL Aug. 26, 2021 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
EQ 100MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 16, 2012 RX TABLET ORAL Feb. 26, 2022 PEDIATRIC EXCLUSIVITY
EQ 12.5MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Oct. 20, 2011 RX TABLET ORAL Feb. 26, 2022 PEDIATRIC EXCLUSIVITY
EQ 25MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL Feb. 26, 2022 PEDIATRIC EXCLUSIVITY
EQ 50MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Nov. 20, 2008 RX TABLET ORAL Feb. 26, 2022 PEDIATRIC EXCLUSIVITY
EQ 75MG ACID PROMACTA NOVARTIS PHARMS CORP N022291 Sept. 8, 2009 RX TABLET ORAL Feb. 26, 2022 PEDIATRIC EXCLUSIVITY
EQ 25MG ACID/PACKET PROMACTA NOVARTIS PHARMS CORP N207027 Aug. 24, 2015 RX FOR SUSPENSION ORAL Feb. 26, 2022 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thrombopoietin receptor Membrane receptor AGONIST EC50 7.42 IUPHAR IUPHAR

External reference:

scroll-->
IDSource
6961 IUPHAR_LIGAND_ID
D03978 KEGG_DRUG
4028105 VUID
N0000179799 NUI
C1831905 UMLSCUI
4U07F515LG UNII
496775-62-3 SECONDARY_CAS_RN
CHEMBL461101 ChEMBL_ID
CHEMBL461806 ChEMBL_ID
DB06210 DRUGBANK_ID
432005001 SNOMEDCT_US
711942 RXNORM
d07357 MMSL
4028105 VANDF
441995009 SNOMEDCT_US
N0000177933 NDFRT
N0000179799 NDFRT
012912 NDDF
9846180 PUBCHEM_CID
8655 INN_ID
C520809 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0007-4515 POWDER, FOR SUSPENSION 25 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0007-4640 TABLET, FILM COATED 25 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0007-4641 TABLET, FILM COATED 50 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0007-4642 TABLET, FILM COATED 75 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0007-4643 TABLET, FILM COATED 12.50 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0007-4646 TABLET, FILM COATED 100 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0684 TABLET, FILM COATED 12.50 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0685 TABLET, FILM COATED 25 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0686 TABLET, FILM COATED 50 mg ORAL NDA 20 sections
PROMACTA HUMAN PRESCRIPTION DRUG LABEL 1 0078-0687 TABLET, FILM COATED 75 mg ORAL NDA 20 sections